Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MK-4074 · 1 trial · 1 indication
Hepatic fat content was assessed via magnetic resonance imaging (MRI) prior to first dose administration and following 4 weeks of treatment. Percent change in hepatic fat fraction from baseline was calculated for each of the 9 liver regions separately and then these were averaged to calculate overall percent change from baseline for each participant.
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.
| Arm | Type | Description |
|---|---|---|
| MK-4074 | EXPERIMENTAL | Participants will receive oral doses of MK-4074 200 mg (2 x 100-mg capsules) twice daily for 4 weeks. |
| Placebo for MK-4074 | PLACEBO_COMPARATOR | Participants will receive oral doses of placebo to match MK-4074 twice daily for 4 weeks. |
| Pioglitazone | EXPERIMENTAL | Participants will receive oral doses of pioglitazone hydrochloride 30 mg (1 x 30-mg tablet) once daily for 4 weeks. |
| Placebo for pioglitazone | PLACEBO_COMPARATOR | Participants will receive oral doses of placebo to match pioglitazone hydrochloride once daily for 4 weeks. |
| Name | Type | Description |
|---|---|---|
| MK-4074 200 mg | DRUG | 2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks |
| Placebo for MK-4074 | DRUG | 2 x 100-mg capsules, orally, BID for 4 weeks. |
| Pioglitazone hydrochloride 30 mg | DRUG | 1 x 30-mg tablet, orally, once daily for 4 weeks |
| Placebo for pioglitazone hydrochloride | DRUG | 1 x 30-mg tablet, orally, once daily for 4 weeks |
Inclusion Criteria: * Females must be of non-childbearing potential * Body mass index (BMI) ≥32.0 kg/m\^2 * In good health based on medical history, physical examination, vital sign measurements, and laboratory safety tests * No clinically significant abnormality on electrocardiogram * Has document...
MK-4074 is an investigational small molecule being studied for the treatment of non-alcoholic fatty liver disease (NAFLD). It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
MK-4074 is being developed by Merck & Company, Inc., which trades on the New York Stock Exchange under the ticker symbol MRK.
MK-4074 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 trial has been completed.
MK-4074 has been studied in one completed Phase 1 clinical trial, identified as NCT01431521. This trial evaluated changes in hepatic fat following administration of MK-4074 and pioglitazone hydrochloride in patients with non-alcoholic fatty liver disease.
No, MK-4074 is not the same as pioglitazone. In the clinical trial NCT01431521, MK-4074 was studied alongside pioglitazone hydrochloride, but they are separate drugs.